Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000892 · ClinicalTrials.gov registry record · NA
A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
NCT00000892 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 300 participants.
The verdict
NCT00000892, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
Study Summary
To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16 weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm. While indinavir is currently the most commonly prescribed protease inhibitor, the optimal therapy for a person on an indinavir-containing regimen who experiences a rebound in viral load or never experiences a decrease in viral load below 500 copies per milliliter is unknown. Current clinical practice for such patients typically involves empiric use of a combination of other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir) and at least 1 other antiretroviral agent to which the patient has had little or no prior exposure. This may involve the use of 1 or more reverse transcriptase inhibitors (RTIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs). This study attempts to formally evaluate some of these options in indinavir-experienced patients.
Interventions
- DRUG Ritonavir
- DRUG Levocarnitine
- DRUG Nelfinavir mesylate
- DRUG Saquinavir
- DRUG Adefovir dipivoxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Est. Completion | 1999-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000892
The ClinicalTrials.gov registry entry for NCT00000892 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ritonavir is the first listed.
NCT00000892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000892 about?
NCT00000892 is a clinical study titled "A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir". To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16 weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm. While indinavir is currently the most commonly prescribed protease inhibitor, the optimal therapy for a person on an ...
What is the current status of trial NCT00000892?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. Estimated completion is 1999-08.
What interventions are being tested in trial NCT00000892?
The interventions under investigation include: Ritonavir (DRUG), Levocarnitine (DRUG), Nelfinavir mesylate (DRUG), Saquinavir (DRUG), Adefovir dipivoxil (DRUG).
Who is sponsoring clinical trial NCT00000892?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.